Disease models are essential for understanding cardiovascular disease pathogenesis and
develo** new therapeutics. The human induced pluripotent stem cell (iPSC) technology …

Since human embryonic stem cells were first differentiated to beating cardiomyocytes a
decade ago, interest in their potential applications has increased exponentially. This has …

Heart disease remains a major cause of death despite advances in medical technology.
Heart-regenerative therapy that uses pluripotent stem cells (PSCs) is a potentially promising …

Induced pluripotent stem cells (iPSCs) are reprogrammed cells that have features similar to
embryonic stem cells, such as the capacity of self-renewal and differentiation into many …

Human embryonic stem cell-derived cardiomyocytes (hESC-CMs) provide a promising
source for cell therapy and drug screening. Several high-yield protocols exist for hESC-CM …

Cardiomyocytes from human pluripotent stem cells (hPSCs-CMs) could revolutionise
biomedicine. Global burden of heart failure will soon reach USD $90 bn, while unexpected …

Differentiated cells can be reprogrammed to an embryonic-like state by transfer of nuclear
contents into oocytes or by fusion with embryonic stem (ES) cells. Little is known about …

Cardiovascular disease is a leading cause of death worldwide. The limited capability of
heart tissue to regenerate has prompted methodological developments for creating de novo …

Human induced pluripotent stem cells (iPSCs) have emerged as an effective platform for
regenerative therapy, disease modeling, and drug discovery. iPSCs allow for the production …

Haematopoietic stem cells (HSCs) differ from their committed progeny by relying primarily on
anaerobic glycolysis rather than mitochondrial oxidative phosphorylation for energy …